DNAnexus Appoints Chief Commercial Officer to Accelerate Global Adoption of Leading Biomedical Data-Driven Technology Platform

Stephen Nuckols brings more than 25 years of experience leading commercial teams for healthcare and life sciences software companies

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the appointment of Stephen Nuckols as Chief Commercial Officer. The appointment follows the company’s recent $200 million financing round, which was led by Blackstone. Nuckols will be responsible for building on the company’s success, driving its commercial growth strategy, and leading its sales, solution science, and marketing functions.

“Steve brings decades of valuable industry experience managing cross-functional teams and scaling commercial operations for leading software companies,” said Richard Daly, CEO at DNAnexus. “He is joining the company right as we enter this next important growth phase. We will look to him to expand our global footprint to meet the increasing demand for our cloud-based, collaborative platforms that harness the power of large-scale genomics, multi-omics, and clinical data.”

Nuckols brings more than 25 years of experience leading commercial teams, corporate growth strategy, M&A, and global accounts in the healthcare and life sciences sector. He previously served as ArisGlobal’s Chief Revenue Officer, where he was responsible for leading all aspects of the commercial organization. Prior to ArisGlobal, he served as Executive Vice President and Chief Commercial Officer at ERT, a leading data and technology company supporting clinical drug development companies. Nuckols was part of the original ERT leadership team during its transformation and rapid growth phase that led to two successful exits. He also held senior executive roles at GE Healthcare, Sage Healthcare, IBM Corporation, Computer Associates, Cognos Corporation, and Oracle. Nuckols holds a bachelor of science degree from Radford University.

“DNAnexus is the platform of choice for many of the world’s largest transformative population research programs,” said Nuckols. “I’m looking forward to joining this talented team and to empowering more researchers with the ability to generate a new wave of data-driven insights that can advance precision medicine and improve patient care.”

Today, DNAnexus has more than 12,000 users across 48 countries and works with the largest and most innovative pharmaceutical companies, diagnostic laboratories, and academic medical centers around the world, along with the UK Biobank and the FDA. The platform provides a comprehensive cloud environment that was designed to meet the most rigorous standards for quality, security, privacy, and safety.

About DNAnexus

DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 65 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005415/en/